All In Biotech

Drug Trial Radar · NCT02496208

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Jul 22, 2015

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Sponsor type
NIH
First posted
Jul 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.

Conditions

  • Bladder Small Cell Neuroendocrine Carcinoma
  • Bladder Squamous Cell Carcinoma
  • Bladder Urothelial Carcinoma
  • Clear Cell Renal Cell Carcinoma
  • Invasive Bladder Plasmacytoid Urothelial Carcinoma
  • Invasive Bladder Sarcomatoid Urothelial Carcinoma
  • Invasive Sarcomatoid Urothelial Carcinoma
  • Kidney Medullary Carcinoma
  • Malignant Genitourinary System Neoplasm
  • Malignant Solid Neoplasm
  • Penile Carcinoma
  • Penile Squamous Cell Carcinoma
  • Renal Cell Carcinoma
  • Renal Pelvis Urothelial Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage III Bladder Cancer AJCC v8
  • Stage III Penile Cancer AJCC v8
  • Stage III Renal Cell Cancer AJCC v8
  • Stage III Renal Pelvis and Ureter Cancer AJCC v8
  • Stage III Renal Pelvis Cancer AJCC v8
  • Stage III Ureter Cancer AJCC v8
  • Stage III Urethral Cancer AJCC v8
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Renal Pelvis and Ureter Cancer AJCC v8
  • Stage IV Ureter Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
  • Ureter Urothelial Carcinoma
  • Urethral Urothelial Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsies

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scan

  • Echocardiography TestProcedure

    Undergo echocardiography

  • IpilimumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase II dose (Phase I)Time frame: Up to 4-6 weeks
  2. Incidence of adverse events (Phase I)Time frame: Up to 30 days post treatment

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

  • NCI - Center for Cancer Research

    Bethesda, Maryland

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.